Blood Test Predicts Immunotherapy Response - Takeaways - MDSpire

Blood Test Predicts Immunotherapy Response

  • May 18, 2026

Share

  • 1

    A machine-learning approach using blood-derived DNA can predict immunotherapy response in melanoma.

  • 2

    The study identified nine conserved tumor microenvironment ecotypes linked to biology, survival, and immunotherapy response.

  • 3

    The cfDNA-based method outperformed traditional biomarkers like tumor mutational burden and PD-L1 expression.

  • 4

    High levels of inflammatory ecotypes SE7 and SE8 correlated with better treatment outcomes, while SE4 indicated resistance.

  • 5

    This noninvasive blood test may enable longitudinal monitoring of tumor microenvironment changes during therapy.

Original Source(s)

Blood Test Predicts Immunotherapy Response

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...